Ibogaine Treatment for Concussions

Ibogaine has no published human clinical data specifically for post‑concussion syndrome PCS or isolated concussion, but there is a rapidly growing body of evidence in traumatic brain injury TBI —including predominantly mild and blast-related TBIs in Special Operations veterans—that is directly relevant to concussions. This evidence suggests that single‑session magnesium‑ibogaine protocols can produce large, rapid, and sustained improvements in disability, mood, PTSD, and cognitive function after chronic TBI, with careful cardiac risk‑mitigation.[1]

Overview

Ibogaine has no published human clinical data specifically for post‑concussion syndrome PCS or isolated concussion, but there is a rapidly growing body of evidence in traumatic brain injury TBI —including predominantly mild and blast-related TBIs in Special Operations veterans—that is directly relevant to concussions. This evidence suggests that single‑session magnesium‑ibogaine protocols can produce large, rapid, and sustained improvements in disability, mood, PTSD, and cognitive function after chronic TBI, with careful cardiac risk‑mitigation.[1]

However, this remains early-stage, open‑label, uncontrolled research, and ibogaine carries real cardiac and mortality risks; it is illegal or unregulated in most jurisdictions and is not an approved treatment for concussion. Below is a detailed research dossier focused on what is known and not yet known about ibogaine for concussion/TBI, including history, pharmacology, clinical data, mechanisms, safety, legal status, and real‑world use.

TBI and Why Ibogaine Is Being Considered - Concussion is generally classified as a form of mild traumatic brain injury mTBI, often from impact or blast forces, with symptoms such as headache, dizziness, cognitive slowing, mood changes, sleep disturbance, and sensitivity to light/sound. - The Stanford/“MISTIC” ibogaine work explicitly focuses on veterans with predominantly mild TBI and chronic disability, including cognitive and emotional sequelae, which strongly overlaps with what is often labeled chronic concussion or post‑concussion syndrome.[2]

5 - Long‑term disability after concussion/mTBI is common and often refractory to conventional treatments; this treatment‑resistance is one driver of interest in psychedelics and neuroplasticity‑enhancing compounds like ibogaine for brain injury. 1 Key point for this topic: Although no trial recruits “concussion” per se, the clinical population in the main ibogaine‑TBI study is largely repeated mild TBI mTBI —the same physiological domain as concussion.[3]

Historical Context: Ibogaine and Brain Injury 2.1 Origins and traditional use - Ibogaine is an indole alkaloid extracted primarily from the root bark of Tabernanthe iboga, used in Gabonese and Cameroonian Bwiti spiritual practices for initiation and healing. 6 - Western interest began in the early 20th century, mainly as a stimulant and later as a treatment for opioid withdrawal, leading to underground and then limited clinical use for substance use disorders.

Research findings

- Sigma‑2 and nicotinic receptors: Ibogaine interacts with sigma‑2 receptors and nicotinic acetylcholine receptors, which may influence neuroprotection and cognitive processes. - 5‑HT2A and other 5‑HT receptors: Unlike classic psychedelics, ibogaine’s 5‑HT2A agonism is weaker and more complex; it is often termed atypical for this reason.

6 3.2 Neuroplasticity and “rewiring” after brain injury A key mechanistic rationale for TBI/concussion: - The New York Times‑referenced animal study described in Concussion Alliance’s review found that ibogaine “can spur the release of natural proteins in the brain that repair and reconfigure neural networks”. 3 - These “proteins” are interpreted as neurotrophins and related plasticity‑linked factors e.g., BDNF, GDNF in preclinical work.[2]

- The Concussion Alliance analysis of the Stanford study notes that ibogaine “promotes neuroplasticity” and may thereby help repair damage from repeated TBI. 6 - PTSD, depression, and cognitive deficits in TBI are associated with disrupted large‑scale brain networks; a single, intense neuroplasticity‑enhancing intervention could, in principle, enable reorganization of these networks when combined with psychotherapy and environmental change.[3]

3.3 Oxytocin and social/emotional processing - A TBI‑focused clinic “Experience Ibogaine” explicitly claims that ibogaine “interacts with hormonal pathways and receptor sites and increases oxytocin, which promotes neuroplasticity,” suggesting improved social bonding and emotional regulation. 2 - These statements are extrapolated from broader psychedelic research and limited ibogaine data; they are plausible but not rigorously demonstrated in TBI patients.

3.4 Anti‑addictive properties in TBI populations - The Stanford study and Concussion Alliance review highlight “apparent anti‑addictive properties” in the TBI veterans, suggesting reduced risk of ibogaine abuse and possible benefit for co‑occurring substance use. 6 - This aligns with decades of ibogaine observations in addiction treatment.[4]

Safety considerations

itself beyond the abstract provides precise dosing; based on the pattern of cardiac‑risk management and typical protocols, it is reasonable to infer that therapeutic doses in this study are in that range, but any dose figure here would be inferred and not directly cited. 4.3 Primary outcome: Functional disability - Primary measure: WHO Disability Assessment Schedule 2.0 WHODAS 2.0.[2]

5 - Baseline: Mean WHODAS score 30.2/100, consistent with mild‑to‑moderate disability. 6 - Post‑treatment results: - Immediate post‑treatment: significant improvement in functioning p<0.001, Cohen’s d = 0.74.[3]

5 - One‑month follow‑up: - WHODAS decreased to 5.1, defined as “no disability” on the WHODAS scale. 6 - Statistical effect size d = 2.20, indicating a very large effect.

5 - Stanford Medicine notes: “Before treatment, the veterans had an average disability rating of 30.2… One month after treatment, that rating improved to 5.1, indicating no disability.” 1 4.4 Secondary outcomes: PTSD, depression, anxiety - Measures included standard scales for: - PTSD likely PCL‑5 or similar, - Depression e.g., PHQ‑9, - Anxiety e.g., GAD‑7. - One-month post‑treatment: - PTSD symptoms reduced by ~88% on average.[4]

1 - Depression symptoms reduced by ~87%. 1 - Effect sizes at 1 month: - PTSD: d = 2.54 very large.

References

  1. med.stanford.edu source
  2. pubmed.ncbi.nlm.nih.gov source
  3. samhsa.gov source
  4. virtualtrip.maps.org, "Ibogaine-Magnesium: the Stanford Traumatic Injury to the CNS (MISTIC) Protocol – A Pilot Study in Special Operations Veterans with Traumatic Brain Injuries", accessed September 10, 2026.